HK Stock Market Move | VISEN PHARMA-B(02561) rose more than 4%. Paropeptin peptide recently completed its first prescription at Boao.

VISEN PHARMA-B (02561) rose more than 4%, up 4.68% at the time of publication, closing at HK$39.8. On the news front, recently, the first prescription for Palopegteriparatide (TransCon PTH) was issued at the Hainan Boao Research Hospital affiliated with Shanghai Jiao Tong University School of Medicine Ruijin Hospital. It is reported that the drug has been approved for marketing in major European and American countries, making it the world's first and only parathyroid hormone replacement therapy drug. Lu Anbang, CEO and Executive Director of VISEN Pharmaceuticals, stated that the first prescription of Palopegteriparatide in Boao is an important step in VISEN Pharmaceuticals' commitment to innovation in the field of endocrinology. This breakthrough treatment drug is expected to help patients overcome the limitations of traditional treatments. The company will continue to work closely with all parties to accelerate the comprehensive approval of the drug domestically and continue to deepen the innovation of endocrine therapies. According to the prospectus, the company's fastest development progress is in Long-acting Growth Hormone (Long-acting Growth Hormone), and the company expects to be approved for domestic marketing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company has two unique varieties, namely Naveptides and Palopegteriparatide, with the latter expected to submit a listing application by the end of 2025. It is reported that in June of this year, VISEN Pharmaceuticals reached a cooperation agreement with WUXI BIO to promote localized production, striving to meet the clinical needs of domestic patients with cost-effective high-value products. In July of this year, VISEN also reached a cooperation agreement with Anhui Anke Biotechnology to jointly promote the commercialization of products, with promising future market prospects.